Janux Therapeutics Inc (NASDAQ:JANX) price on Thursday, July 03, rose 1.62% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $24.45.
A look at the stock’s price movement, the close in the last trading session was $24.06, moving within a range at $23.95 and $24.87. The beta value (5-Year monthly) was 2.955. Turning to its 52-week performance, $71.71 and $22.48 were the 52-week high and 52-week low respectively. Overall, JANX moved -3.85% over the past month.
Janux Therapeutics Inc’s market cap currently stands at around $1.45 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-May-08.
The average forecast suggests down to a -96.63% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 1.27M, representing a -87.98% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that JANX is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 2 recommend JANX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
JANX’s current price about 1.27% and -5.32% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 50.76, while 7-day volatility ratio is 5.32% and 5.40% in the 30-day chart. Further, Janux Therapeutics Inc (JANX) has a beta value of 2.86. Analysts have given the company’s stock an average 52-week price target of $58.5, forecast between a low of $41 and high of $76. Looking at the price targets, the low is -67.69% off current price level while to achieve the yearly target high, price needs to move -210.84%. Nonetheless, investors will most likely welcome a -139.26% jump to $58.5 which is the analysts’ median price.
If we refocus on Janux Therapeutics Inc (NASDAQ:JANX), historical trading data shows that trading volumes averaged 0.77 over the past 10 days and 974.86K over the past 3 months. The company’s latest data on shares outstanding shows there are 59.17 million shares.
The 16.29% of Janux Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 110.17% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 10.61 million on 2025-06-13, giving us a short ratio of 11.13. The data shows that as of 2025-06-13 short interest in Janux Therapeutics Inc (JANX) stood at 2594.0 of shares outstanding, with shares short falling to 11.55 million registered in 2025-05-15. Current price change has pushed the stock -41.40% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the JANX stock continues to rise going into the next quarter.
